Mira Pharmaceuticals reports new preclinical receptor selectivity findings for pain drug MIRA-55
MIRA•Mira Pharmaceuticals reported preclinical findings showing MIRA-55 has selective receptor activity distinct from conventional opioid and COX-inhibiting pain medicines. The company is targeting an investigational new drug submission in the first half of 2027.
1. Preclinical findings
Mira Pharmaceuticals said receptor screening showed MIRA-55 has selective activity distinct from conventional opioid and COX-inhibiting pain medicines. Previously reported animal studies showed pain relief and reduced inflammation without significant THC-like motor impairment. The company is targeting an investigational new drug submission in the first half of 2027.




